Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 6/20 | 0.56 |
| ▸ | KDR | P35968 | 2/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.56 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.56 |
| ▸ | GAK | O14976 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | CBFB | Q13951 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2595670 | 0.84 | RIPK2 (0.42) | RIPK2KDRRETMAPK14PKMYT1 | |
| SCHEMBL16289148 | 0.81 | RIPK2 (0.58) | RIPK2KDRRETMAPK14PKMYT1 | |
| SCHEMBL30880575 | 0.80 | RIPK2 (0.50) | RIPK2KDRRETMAPK14PKMYT1 | |
| SCHEMBL2588818 | 0.80 | NR4A2 (0.53) | RIPK2KDRRETMAPK14PKMYT1 | |
| SCHEMBL16289146 | 0.80 | RIPK2 (0.50) | RIPK2KDRRETMAPK14PKMYT1 | |
| SCHEMBL17059449 | 0.80 | RIPK2 (0.50) | RIPK2KDRRETMAPK14PKMYT1 | |
| SCHEMBL600488 | 0.80 | RIPK2 (0.50) | RIPK2KDRRETMAPK14PKMYT1 | |
| SCHEMBL26317970 | 0.79 | GAK (0.64) | RIPK2KDRRETMAPK14PKMYT1 | |
| SCHEMBL17059460 | 0.78 | RIPK2 (0.48) | RIPK2KDRRETMAPK14PKMYT1 | |
| SCHEMBL14730905 | 0.76 | RIPK2 (0.47) | RIPK2KDRRETMAPK14PKMYT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| CN-103857288-B | Amino-quinolines as kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2016-09-21 | — | — | CN | disclosed |
| US-20160060249-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| US-20160060222-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2016-03-03 | — | — | US | disclosed |
| US-20160060222-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2016-03-03 | — | — | US | disclosed |
| US-20160060222-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2016-03-03 | — | — | US | disclosed |
| US-20160060249-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| US-20160060249-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| EP-2603218-B1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| WO-2012021580-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012021580-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | WO | disclosed |
| US-20120041024-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120041024-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| WO-2011140442-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140442-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-11-10 | — | — | WO | disclosed |
| US-20110053934-A1 | COMPOUNDS AND METHODS OF TREATMENT | GLAXOSMITHKLINE LLC (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053934-A1 | COMPOUNDS AND METHODS OF TREATMENT | GLAXOSMITHKLINE LLC (US) | 2011-03-03 | — | — | US | disclosed |
| US-20080234267-A1 | Compounds and Methods of Treatment | SMITHKLINE BEECHAM CORPORATION | 2008-09-25 | — | — | US | disclosed |
| US-20080234267-A1 | Compounds and Methods of Treatment | SMITHKLINE BEECHAM CORPORATION | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041024-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | RIPK2 480/4885KDR 523/4885RET 72/4885 |
| US-20110053934-A1 | COMPOUNDS AND METHODS OF TREATMENT | RET, ABL1, PRKACA | RIPK2 184/4885KDR 350/4885RET 1/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | RIPK2 830/4885KDR 2851/4885RET 1440/4885 |
| US-20160060222-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | ABL1, MAP3K2, MAP4K2 | RIPK2 326/4885KDR 404/4885RET 193/4885 |
| US-20160060249-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | RIPK2 480/4885KDR 523/4885RET 72/4885 |
| US-20080234267-A1 | Compounds and Methods of Treatment | RET, ABL1, PRKACA | RIPK2 184/4885KDR 350/4885RET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.